Industry
Definium Therapeutics US, Inc.
Total Trials
6
Recruiting
1
Active
4
Completed
2
Success Rate
100.0%+13% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 5/100
Failure Rate
0.0%
0 terminated/withdrawn out of 6 trials
Success Rate
100.0%
+13.5% vs industry average
Late-Stage Pipeline
50%
3 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed trials have results
Key Signals
1 recruiting2 with results
Enrollment Performance
Analytics
Phase 2
3(50.0%)
Phase 3
3(50.0%)
6Total
Phase 2(3)
Phase 3(3)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (6)
Showing 6 of 6 trials
NCT06809595Phase 3Active Not Recruiting
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
Role: lead
NCT06741228Phase 3Active Not Recruiting
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)
Role: lead
NCT06941844Phase 3Active Not Recruiting
A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)
Role: lead
NCT05407064Phase 2Completed
A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms
Role: lead
NCT05200936Phase 2Completed
Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial
Role: lead
NCT07303907Phase 2Recruiting
A Phase 2A Trial of MM402 for Autism Spectrum Disorder
Role: lead
All 6 trials loaded